10x Genomics, Inc. TXG Single Cell — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s single cell — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s single cell — revenue?
- 10x Genomics, Inc. (TXG) reported single cell — revenue of $5.22M in Q1 2026.
- How has 10x Genomics, Inc.'s single cell — revenue changed year-over-year?
- 10x Genomics, Inc.'s single cell — revenue decreased by 11.7% year-over-year, from $5.91M to $5.22M.
- What is the long-term trend for 10x Genomics, Inc.'s single cell — revenue?
- Over 3 years (2021 to 2024), 10x Genomics, Inc.'s single cell — revenue has grown at a -18.1% compound annual growth rate (CAGR), from $64.17M to $35.21M.
- What does single cell — revenue mean?
- This metric represents the total revenue generated specifically from the sale of instruments within the single-cell analysis product line. It serves as a key indicator of market adoption for the company's core hardware platforms used in biological research. Tracking this revenue stream helps investors assess the installed base growth and the potential for recurring demand for associated consumables.